ResMed Quarterly Income Statement
NYSE: RMDHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ResMed revenue and earnings
In the quarter ended Jun 30, 2026, ResMed generated $1.46 billion in revenue, up 8.6% from the same quarter a year earlier. Net income was $383.4 million (+1.0% year over year), for a net margin of 26.2% versus a median of 27.9% in the prior 5 quarters. Gross margin was 58.8% (down from 60.8%) and operating margin 30.7%.
Diluted earnings per share came in at $2.64, up from $2.58.
Summary generated from market data by MetaCap's automated system. Methodology
ResMed income statement (quarterly)
| Quarter (USD) | Q4 20262026-06-30 | Q3 20262026-03-31 | Q2 20262025-12-31 | Q1 20262025-09-30 | Q4 20252025-06-30 | Q3 20252025-03-31 | Q2 20252024-12-31 | Q1 20252024-09-30 | Q4 20242024-06-30 | Q3 20242024-03-31 | Q2 20242023-12-31 | Q1 20242023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.46B | 1.43B | 1.42B | 1.34B | 1.35B | 1.29B | 1.28B | 1.22B | 1.22B | 1.20B | 1.16B | 1.10B |
| Revenue growth (YoY) | +8.58% | +10.81% | +10.98% | +9.07% | +10.20% | +7.92% | +10.26% | +11.08% | +9.01% | +7.17% | +12.48% | +16.00% |
| Cost of Revenue | 602.43M | 540.43M | 544.08M | 514.76M | 527.92M | 525.33M | 530.81M | 507.29M | 507.67M | 504.20M | 515.87M | 502.26M |
| Gross Profit | 861.22M | 890.98M | 878.72M | 820.82M | 820.07M | 766.41M | 751.27M | 717.22M | 715.53M | 692.78M | 646.93M | 600.06M |
| Operating Expenses | 412.51M | 391.17M | 387.06M | 374.28M | 365.53M | 340.14M | 334.03M | 329.91M | 334.31M | 318.20M | 371.84M | 311.06M |
| Research & Development | 105.72M | 94.27M | 90.97M | 87.32M | 86.44M | 83.94M | 81.37M | 79.52M | 80.86M | 77.07M | 73.88M | 75.71M |
| Selling, General & Admin | 296.28M | 285.65M | 278.40M | 259.19M | 267.16M | 245.30M | 241.61M | 238.98M | 242.19M | 229.92M | 222.16M | 222.87M |
| Operating Income | 448.71M | 499.81M | 491.66M | 446.54M | 454.54M | 426.27M | 417.24M | 387.31M | 381.22M | 374.58M | 275.09M | 289.00M |
| Other Income (Expense) | 25.45M | 2.50M | 4.49M | 256.00K | 3.51M | -8.57M | 1.08M | -3.81M | -23.48M | 837.00K | -15.64M | -16.81M |
| Pretax Income | 474.16M | 502.31M | 496.15M | 446.79M | 458.05M | 417.69M | 418.32M | 383.50M | 357.73M | 375.42M | 259.45M | 272.19M |
| Income Tax | 90.73M | 103.58M | 103.56M | 98.26M | 78.35M | 52.65M | 73.70M | 72.14M | 65.50M | 74.93M | 50.65M | 52.77M |
| Net Income | 383.43M | 398.73M | 392.59M | 348.54M | 379.70M | 365.04M | 344.62M | 311.36M | 292.24M | 300.49M | 208.80M | 219.42M |
| Net Income growth (YoY) | +0.98% | +9.23% | +13.92% | +11.94% | +29.93% | +21.48% | +65.05% | +41.90% | +27.25% | +29.24% | -7.16% | +4.25% |
| EPS (Basic) | 2.66 | 2.74 | 2.69 | 2.38 | 2.59 | 2.49 | 2.35 | 2.12 | 1.99 | 2.04 | 1.42 | 1.49 |
| EPS (Diluted) | 2.64 | 2.74 | 2.68 | 2.37 | 2.58 | 2.48 | 2.34 | 2.11 | 1.97 | 2.04 | 1.42 | 1.49 |
| Shares Outstanding (Basic) | — | 145.34M | 145.84M | 146.18M | — | 146.72M | 146.81M | 146.86M | — | 146.96M | 147.13M | 147.07M |
| Shares Outstanding (Diluted) | — | 145.72M | 146.37M | 146.90M | — | 147.22M | 147.48M | 147.60M | — | 147.45M | 147.54M | 147.49M |
| EBITDA | 493.49M | 558.79M | 541.54M | 494.24M | 518.17M | 469.94M | 463.68M | 432.04M | 424.89M | 418.06M | 319.88M | 333.93M |
| Gross Margin | 58.84% | 62.25% | 61.76% | 61.46% | 60.84% | 59.33% | 58.60% | 58.57% | 58.50% | 57.88% | 55.64% | 54.44% |
| Operating Margin | 30.66% | 34.92% | 34.56% | 33.43% | 33.72% | 33.00% | 32.54% | 31.63% | 31.17% | 31.29% | 23.66% | 26.22% |
| Net Margin | 26.20% | 27.86% | 27.59% | 26.10% | 28.17% | 28.26% | 26.88% | 25.43% | 23.89% | 25.10% | 17.96% | 19.91% |
This table shows 12 quarterly periods of ResMed's income statement, from Q4 2026 back to Q1 2024, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow RMD's reporting calendar. What is a income statement?